Clinical trial
A Phase 2 Study of Boswellia for Treating Urinary Toxicity in Prostate Cancer Radiotherapy
NCT07867158 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Boswellia for Treating Urinary Toxicity in Prostate Cancer Radiotherapy
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- June 30, 2027
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer